gyki 52466 has been researched along with Cerebral Palsy in 1 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
Cerebral Palsy: A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nandhu, MS | 1 |
| Paul, J | 1 |
| Mathew, J | 1 |
| Peeyush Kumar, T | 1 |
| Paulose, CS | 1 |
1 other study available for gyki 52466 and Cerebral Palsy
| Article | Year |
|---|---|
GYKI-52466: a potential therapeutic agent for glutamate-mediated excitotoxic injury in Cerebral Palsy.
Topics: Benzodiazepines; Brain Diseases; Cerebral Palsy; Glutamic Acid; Humans; Models, Neurological; Recept | 2010 |